RT Journal Article
T1 Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients
A1 Arango López, Celso
A1 Giráldez, Miriam
A1 Merchán Naranjo, Jessica
A1 Baeza, Inmaculada
A1 Castro Fornieles, Josefina
A1 Alda, José Ángel
A1 Martínez Cantarero, Carmen
A1 Moreno Ruiz, María del Carmen
A1 Andrés, Pilar de
A1 Serna, Elena de la
A1 Correll, Christoph U.
A1 Fraguas, David
A1 Parellada, Mara
AB Objective: To assess weight and metabolic effects of 6 months of treatment with second-generation antipsychotics in naïve/quasi-naïve youths.Method: This study looked at a nonrandomized, naturalistic, multicenter, inception cohort study of 279 patients aged 4 to 17 years (mean = 14.6 ± 2.9 years). Of those, 248 (88.8%) received a single antipsychotic (risperidone, olanzapine, or quetiapine) and completed 2 visits, and 178 (63.8%) completed the 6-month follow-up. Patients had schizophrenia-spectrum disorders (44.5%), mood-spectrum disorders (23.2%), disruptive behavioral disorders (17.3%), or other disorders (15.1%). Fifteen age- and gender-matched, healthy, nonmedicated individuals served as a comparison group.Results: From baseline to 1 month, 3 months, and 6 months, all anthropometric measures increased significantly with each antipsychotic, that is, 6-month changes with risperidone (n = 157; 7.1 kg and 0.66 body mass index [BMI] z score), olanzapine (n = 44; 11.5 kg and 1.08 BMI z score), and quetiapine (n = 47; 6.3 kg and 0.54 BMI z score), but not in healthy control participants (-0.11 kg and 0.006 BMI z score). Fasting metabolic parameters increased significantly with risperidone (glucose [3.8] mg/dL, insulin [4.9] mU/L, homeostasis model assessment of insulin resistance [HOMA-IR: 1.2], triglycerides [15.6] mg/dL), and olanzapine (glucose [5.0] mg/dL, total cholesterol [21.2] mg/dL, and low-density lipoprotein cholesterol [44.6] mg/dL), but not with quetiapine or in healthy control participants. The percentage of research participants considered to be "at risk of adverse health outcome" increased during the 6 months from 8.9% to 29.2% for risperidone (p < .0001), 6.8% to 38.1% for olanzapine (p < .0001), and 6.3% to 4.0% for quetiapine (p = .91).Conclusion: Olanzapine, quetiapine, and risperidone increase body weight but have different cardiometabolic side effect profiles and different temporal side effect patterns.
PB Elsevier
SN 0890-8567
YR 2014
FD 2014-11-04
LK https://hdl.handle.net/20.500.14352/115311
UL https://hdl.handle.net/20.500.14352/115311
LA eng
NO Arango C, Giráldez M, Merchán-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA, Martínez-Cantarero C, Moreno C, de Andrés P, Cuerda C, de la Serna E, Correll CU, Fraguas D, Parellada M. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry. 2014 Nov;53(11):1179-90,1190.e1-4. doi: 10.1016/j.jaac.2014.08.009
NO Instituto de Salud Carlos III
NO Ministerio de Economía y Competitividad (España)
NO CIBERSAM
NO RETICS RD06/0011
NO Fundación Alicia Koplowitz
NO Fundación Mutua Madrileña
NO Gobierno Regional
NO Unión Europea
DS Docta Complutense
RD 16 abr 2025